• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Outpatient treatment of COVID-19: an experience with 552 cases in Mexico
Conclusions: The use of nitazoxanide, azithromycin, and prednisone proved to be effective as it resulted in improvement of symptoms and in successful outcomes for the management of COVID-19 outpatients.
Source: The Journal of Infection in Developing Countries - March 30, 2023 Category: Infectious Diseases Authors: Ra úl Romero-Cabello, Raúl Romero-Feregrino, Rodrigo Romero-Feregrino, Berenice Muñoz-Cordero, Samuel Sevilla-Fuentes Source Type: research

Assessment of Recovery Time, Worsening, and Death among Inpatients and Outpatients with COVID-19, Treated with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso
The COVID-19 is a worldwide, ongoing pandemic due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first case was identified in the Chinese city of Wuhan in December 2019 (Zhu  et al., 2020). On March 11, 2020, the COVID-19 outbreak was declared as pandemic by the WHO (World Health Organization, 2020). In Burkina Faso, the first suspected case of COVID-19 was reported on February 5, 2020 (Tarnagda et al., 2021), while the first confirmed case was notified on March 9 , 2020 (WHO, 2020; Worldometer, 2020).
Source: International Journal of Infectious Diseases - February 25, 2022 Category: Infectious Diseases Authors: Toussaint Rouamba, Esperance Ou édraogo, Houreratou Barry, Nobila Valentin Yaméogo, Apoline Sondo, Rainatou Boly, Jacques Zoungrana, Abdoul Risgou Ouédraogo, Marc Christian Tahita, Armel Poda, Arnaud Eric Diendéré, Abdoul-Salam Ouedraogo, Innocent Va Source Type: research

Case Report: Severe SARS-CoV-2 Infection with Remdesivir in a Patient with ESRD
CONCLUSION: Our findings describe the first instance of compassionate use of remdesivir for the treatment of COVID-19 in the setting of end-stage renal disease, acute respiratory distress syndrome, and hypoxemic respiratory failure.PMID:34852751 | DOI:10.2174/1871526521666211201112410
Source: Infectious Disorders Drug Targets - December 2, 2021 Category: Infectious Diseases Authors: Raj H Patel Pablo M Pella Naeem Haider Renato Blanco Source Type: research

Pages: 1  2  3